In February 2012, Aldagen Inc was acquired by Cytomedix of Maryland. Previously dba StemCo Biomedical, Inc, Aldagen's proprietary products identify and isolate unique populations of adult stem cells with the potential to revolutionize treatments of cardiovascular disease and degenerative diseases. The firm had been engaged in the development, manufacture and distribution of a series of medical products designed to improve therapeutic transplantation of adult hematopoietic stem and progenitor cells derived from bone marrow, peripheral blood, or umbilical cord blood. The firm developed kits for the isolation and transplantation of hematopoietic stem cells to cure a variety of diseases. The firm attempted twice - both unsuccessful - in 2008 to go public: victim of the economic turbulence that defines that period.
